Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?

Shares of Trevi Therapeutics, Inc. (TRVI) have gained 4.1% over the past four weeks to close the last trading session at $6.46, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$19.06 indicates a potential upside of 195.1%.The average comprises eight short-term price targets ranging from a low of $11 to a high of$29, with a standard deviation of $6.01. While the lowest estimate ...